Demand continues to return for Amgen in third quarter

3 November 2021
amgen_big

California’s Amgen (Nasdaq: AMGN) has reported third-quarter 2021 financial results showing total revenues increased 4% to $6.71 billion, driven by higher demand.

The positive result, which was partially offset by lower net prices, was a touch higher than analysts had expected, with the Financial Times consensus forecast coming in at $6.68 billion.

Following Generally Accepted Accounting Principles (GAAP), the earnings per share (EPS) figure decreased 3% to $3.31, due to a $400 million licensing-related expense from a collaboration with Kyowa Kirin (TYO: 4151).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology